Oops. Don't forget the potential revenue for rGBM.
Yes, you can forget that. Try actually thinking about what that means.
If the patient used -L for nGBM but had true progression anyway they are unlikely to use for rGBM. It is not the norm in cancer, and the trial has no data on it because they could not tell who actually had rGBM in the treatment arm.
If they did not use nGBM initially then there would not be any -L already manufactured as there was in the trial. So they need surgery and most will not. Further, even if they do likely to be smallsh as they are being watched. Also have to wonder why they did not use -L initially.
Market Data 
Markets 
AI
